A new D-peptide treatment for rheumatoid arthritis
A Potent D-peptide Inhibitor of TNFα for Treatment of Rheumatoid Arthritis
This study is testing a new treatment called DBT178 that aims to reduce inflammation in people with rheumatoid arthritis, and it could offer a better option for those who haven't had success with current medications.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | D Biotherapeutics, LLC NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10822182 on NIH RePORTER |
What this research studies
This research investigates a novel D-peptide, DBT178, designed to inhibit TNFα, a key driver of inflammation in rheumatoid arthritis (RA). The approach focuses on creating a stable and protease-resistant peptide that can effectively block TNFα activity, potentially overcoming the limitations of current anti-TNFα biologics that many patients develop resistance to. The study aims to evaluate the pharmacokinetics and efficacy of DBT178 in a validated RA disease model, which could lead to improved treatment options for patients suffering from this chronic condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with rheumatoid arthritis, particularly those who have experienced a loss of efficacy with current anti-TNFα treatments.
Not a fit: Patients who do not have rheumatoid arthritis or those who are not adults may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and durable treatment option for patients with rheumatoid arthritis who have lost response to existing therapies.
How similar studies have performed: While the use of D-peptides in this context is relatively novel, similar approaches targeting TNFα have shown promise in other studies.
Where this research is happening
Salt Lake City, United States
- D Biotherapeutics, LLC — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Risdon, Grant H — D Biotherapeutics, LLC
- Study coordinator: Risdon, Grant H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.